A brand manager sits with the inputs for the next cycle. A printed treatment guideline for the new SKU. A diary for the top prescribers. The sample plan. A slot at a city CME the brand will support. For years these were questions of budget and taste. Which item, how many, for whom. Since 2024, each one is also a question of record.
In March 2024 the Department of Pharmaceuticals notified the Uniform Code of Pharmaceutical Marketing Practices, 2024, and dropped the word voluntary that the 2015 version had carried. A marketing choice now has to be explainable later, in an audit, to an ethics committee, to the executive who signed the declaration. Good taste is no longer the only test.
How the Code Is Enforced Now
Enforcement runs through the industry's own machinery. A complaint can trigger a Department audit of a company. Pharmaceutical associations now run an Ethics Committee for Pharmaceutical Marketing Practices to hear violations, with an apex committee under the Department above it. The tax authorities have separately disallowed expenses that were incurred in breach of the code. And the senior-most executive of every company files an annual self-declaration that the company has complied. That is a quieter kind of pressure than a penalty, and a more constant one.
The Choices That Now Leave a Record
Take the brand reminder. The code allows informational and educational items, books, calendars, diaries, journals, clinical treatment guidelines, dummy device models, the kind of thing a doctor uses in practice. Each item carries a value limit of one thousand rupees. A reminder that costs more than that is no longer a grey area to be argued later. It sits outside the line the code draws.
Take free samples. They are permitted, but only to a person qualified to prescribe the product. They are capped at twelve packs per drug in a year, and the value of all samples distributed is capped at two percent of the company's domestic sales. The company keeps a record of what went to whom. A sampling plan built the old way, on relationship and reach, now has to fit inside two numbers and a register.
Take gifts and travel. Gifts and travel facilities to a doctor, or to their family, are not permitted. A company can support genuine continuing medical education, and can organise such an event itself, but the event is conducted transparently, it is not held in a foreign location, and the spend can be examined in an audit. The support has to be the kind that can be explained later.
Where This Leaves the Brand Manager
None of this turns on whether the gesture is generous, or whether the doctor would value it. It turns on whether there is a record that shows it sat inside the code. The committees are real, and so is the complaint route into them. The rulebook has stopped being something the medico-marketing team holds and the brand team borrows from. The brand manager now makes choices that the company has formally undertaken to stand behind.
The habit worth building is simple. Before any input is ordered, picture it being questioned a year later, and ask what record would show it sat inside the code. A diary under a thousand rupees, logged. A sample plan inside the caps, registered. A CME with its purpose and spend on paper. Each input now has to do two things. Land with the doctor, and stand on its own when someone later asks about it. Handled this way, the cycle stays the same. The easy questions stay easy, and the expensive ones never arrive.
Disclaimer: This is a practitioner reading of the code for brand teams, not legal advice. The final compliance call sits with your medical and regulatory team.